CoChat

Bifidobacterium alters the gut microbiota and modulates the functional metabolism of T regulatory cells in the context of immune checkpoint blockade

Open access

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

Significance: Many millions of people take probiotics over the counter, but very little is known about what they do and whether they really work. Here we show that in mice, introducing Bifidobacterium , one of the most commonly used probiotics, not only colonizes the gut, but also alters the entire microbiotic landscape. We previously found that this treatment rescues mice from an otherwise fatal inflammatory syndrome brought on by anti–CTLA-4 antibody, a checkpoint inhibitor that often causes autoimmunity in humans undergoing cancer treatment. Here we show that this is effect is due, at least in part, to the effect of this probiotic treatment on regulatory CD4 + cells, whose metabolic and immune suppressive functions are altered. These CD4 + regulatory T cells are known to be a key mechanism in the control of autoreactivity in the immune system in both mice and humans. Thus, we found a direct connection between probiotic treatment and one of the known principal mechanisms for controlling excess immune responses.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1921223117

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. Bifidobacterium alters gut microbiota community. (A) Principal coordinate plot of microbiota composition with PBS (red) and Bifidobacterium (blue). (B) Percentage (mean ± SEM) of the total bacterial abundance of significantly changed bacteria in control and de-Treg mice after PBS or Bifidobacterium administration. n.s., not significant. u.d., undetectable. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Fig. 1. Bifidobacterium alters gut microbiota community. (A) Principal coordinate plot of microbiota composition with PBS (red) and Bifidobacterium (blue). (B) Percentage (mean ± SEM) of the total bacterial abundance of significantly changed bacteria in control and de-Treg mice after PBS or Bifidobacterium administration. n.s., not significant. u.d., undetectable. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.CC BY-NC-ND · PubMed Central
Fig. 2. B. breve and L. rhamnosum are potential functional strains in gut inflammation amelioration. (A) Percent initial weight of mice with 2.5% DSS-induced colitis injected with an αCTLA-4 mAb and treated with PBS control, B. longum, B. bifidum, B. breve, or Bifidobacterium angulatum. (B) Percent initial weight of mice with 2.5% DSS-induced colitis injected with an αCTLA-4 mAb and treated with PBS control, L. plantarum, L. rhamnosum, or L. salivarius. Data are presented as mean ± SEM. n = 5. n.s., not significant. ****P < 0.0001. (C) Representative colon sections of mice treated with PBS control, B. breve, or L. rhamnosum (H&E-staining; scale bar: 100 μm). (D) Concentrations of IL-6, CSF3, and KC in the serum of mice treated with PBS control, B. breve, or L. rhamnosum. ***P < 0.001; ****P < 0.0001.
Fig. 2. B. breve and L. rhamnosum are potential functional strains in gut inflammation amelioration. (A) Percent initial weight of mice with 2.5% DSS-induced colitis injected with an αCTLA-4 mAb and treated with PBS control, B. longum, B. bifidum, B. breve, or Bifidobacterium angulatum. (B) Percent initial weight of mice with 2.5% DSS-induced colitis injected with an αCTLA-4 mAb and treated with PBS control, L. plantarum, L. rhamnosum, or L. salivarius. Data are presented as mean ± SEM. n = 5. n.s., not significant. ****P < 0.0001. (C) Representative colon sections of mice treated with PBS control, B. breve, or L. rhamnosum (H&E-staining; scale bar: 100 μm). (D) Concentrations of IL-6, CSF3, and KC in the serum of mice treated with PBS control, B. breve, or L. rhamnosum. ***P < 0.001; ****P < 0.0001.CC BY-NC-ND · PubMed Central
Fig. 3. IL-10 and IL-22 are indispensable for Bifidobacterium function. (A) Volcano plot of significantly changed genes in colonic LP Tregs, comparing Bifidobacterium-treated mice with PBS-treated mice in a CTLA-4 blockade condition. (B and C) Flow cytometry analysis of IL-10Rα (B) and IL-10 (C) in colon LP Tregs isolated from CTLA-4–injected mice. Data are from two independent experiments. n = 2 mice per group in each experiment. n.s., not significant, *P < 0.05, **P < 0.01, ****P < 0.0001. (D) Treg suppression assay performed by coculturing spleen Teff cells, antigen-presenting cells, and colon Tregs from PBS- or Bifidobacterium-treated mice at 4 d after receiving anti–CTLA-4 antibody. Data are from three independent experiments. *P < 0.05. (E) Percent initial weight of WT and Il-10 KO mice with 2.5% DSS-induced colitis subjected to IgG or αIL-22 injection. The mice were treated with αCTLA-4 mAb and Bifidobacterium. n = 5. ***P < 0.001, ****P < 0.0001. (F and G) Representative colon tissue sections from Bifidobacterium-treated WT mice, αIL-22–injected WT mice, and IgG-treated Il-10 KO mice at day 10 after anti–CTLA-4 antibody injection and DSS administration (H&E-staining; scale bar: 100 μm) (F) and concentrations of cytokines in serum (G). *P < 0.05, **P < 0.01. (H) Percent initial weight of αIL-22–injected Il-10 KO mice with 2.5% DSS-induced colitis subjected to anti–CTLA-4 mAb treatment and PBS or Bifidobacterium gavage. Data are mean ± SEM. n = 5. n.s., not significant. (I) Histological scores of mice receiving PBS or Bifidobacterium.
Fig. 3. IL-10 and IL-22 are indispensable for Bifidobacterium function. (A) Volcano plot of significantly changed genes in colonic LP Tregs, comparing Bifidobacterium-treated mice with PBS-treated mice in a CTLA-4 blockade condition. (B and C) Flow cytometry analysis of IL-10Rα (B) and IL-10 (C) in colon LP Tregs isolated from CTLA-4–injected mice. Data are from two independent experiments. n = 2 mice per group in each experiment. n.s., not significant, *P < 0.05, **P < 0.01, ****P < 0.0001. (D) Treg suppression assay performed by coculturing spleen Teff cells, antigen-presenting cells, and colon Tregs from PBS- or Bifidobacterium-treated mice at 4 d after receiving anti–CTLA-4 antibody. Data are from three independent experiments. *P < 0.05. (E) Percent initial weight of WT and Il-10 KO mice with 2.5% DSS-induced colitis subjected to IgG or αIL-22 injection. The mice were treated with αCTLA-4 mAb and Bifidobacterium. n = 5. ***P < 0.001, ****P < 0.0001. (F and G) Representative colon tissue sections from Bifidobacterium-treated WT mice, αIL-22–injected WT mice, and IgG-treated Il-10 KO mice at day 10 after anti–CTLA-4 antibody injection and DSS administration (H&E-staining; scale bar: 100 μm) (F) and concentrations of cytokines in serum (G). *P < 0.05, **P < 0.01. (H) Percent initial weight of αIL-22–injected Il-10 KO mice with 2.5% DSS-induced colitis subjected to anti–CTLA-4 mAb treatment and PBS or Bifidobacterium gavage. Data are mean ± SEM. n = 5. n.s., not significant. (I) Histological scores of mice receiving PBS or Bifidobacterium.CC BY-NC-ND · PubMed Central
Fig. 4. Bifidobacterium affects the mitochondrial metabolism of colon Tregs. (A) Concentrations of suberic acid in the serum of mice treated with PBS or Bifidobacterium. *P < 0.05. (B) GO analysis of significantly impaired biological processes. (C) GSEA of colon Tregs. The diagram plots GSEA for four gene sets up-regulated in Bifidobacterium-treated groups (left side, Bifidobacterium; right side, PBS). The vertical axis in the upper graph indicates the enrichment score (ES) for genes in each gene set. The barcode plot indicates the position of genes in each gene set. NES, normalized ES; FDR, false discovery rate. (D) Mitochondrial mass of colon LP Tregs (n = 5), as detected by MitoTracker Deep Red FM labeling and flow cytometry. *P < 0.05. (E) Mitochondrial stress of colon LP Tregs (n = 5), as detected by MitoTracker Red CMXROS labeling and flow cytometry. *P < 0.05. (F) Mitochondria-related gene expression pattern in Bifidobacterium-treated vs. PBS-treated LP Tregs.
Fig. 4. Bifidobacterium affects the mitochondrial metabolism of colon Tregs. (A) Concentrations of suberic acid in the serum of mice treated with PBS or Bifidobacterium. *P < 0.05. (B) GO analysis of significantly impaired biological processes. (C) GSEA of colon Tregs. The diagram plots GSEA for four gene sets up-regulated in Bifidobacterium-treated groups (left side, Bifidobacterium; right side, PBS). The vertical axis in the upper graph indicates the enrichment score (ES) for genes in each gene set. The barcode plot indicates the position of genes in each gene set. NES, normalized ES; FDR, false discovery rate. (D) Mitochondrial mass of colon LP Tregs (n = 5), as detected by MitoTracker Deep Red FM labeling and flow cytometry. *P < 0.05. (E) Mitochondrial stress of colon LP Tregs (n = 5), as detected by MitoTracker Red CMXROS labeling and flow cytometry. *P < 0.05. (F) Mitochondria-related gene expression pattern in Bifidobacterium-treated vs. PBS-treated LP Tregs.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 277

Metadata

Authors
Sun, S., Luo, L., Liang, W., Yin, Q., Guo, J., Rush, A. M., Lv, Z., Liang, Q., Fischbach, M. A., Sonnenburg, J. L., Dodd, D., Davis, M. M., & Wang, F.
Affiliations
  • Shanghai Jiao Tong University (CN)
  • Howard Hughes Medical Institute (US)
  • Stanford Medicine (US)
  • Stanford University (US)
Corresponding author
  • Davis, Mark M.
  • Wang, Feng
Venue
Proceedings of the National Academy of Sciences
Published
2020-10-19
Volume
117
Issue
44
Pages
27509-27515
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W3093243853
Cited by
277
References
23
Citations by year
2026: 30 · 2025: 48 · 2024: 68 · 2023: 57 · 2022: 45 · 2021: 28 · 2020: 1
FWCI
10.63
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • Howard Hughes Medical Institute
  • National Institute of Allergy and Infectious Diseases (U19AI057229)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK085025)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
Bifidobacterium, probiotics, gut microbiota, regulatory T cells, immune checkpoint blockade, anti-CTLA-4 antibody, CTLA-4, autoimmunity, CD4+ T cells, T cell metabolism, immunosuppression, inflammatory syndrome
MeSH terms
Gastrointestinal Microbiome, Immune Checkpoint Inhibitors, Animals, Autoimmune Diseases, Bifidobacterium, Disease Models, Animal, Female, Humans, Immune Tolerance, Interleukin-10, Mice, Knockout, Probiotics, T-Lymphocytes, Regulatory, Mice, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bifidobacterium alters the gut microbiota and modulates the functional metabolism of T regulatory cells in the context of immune checkpoint blockade. https://app.cochat.ai/papers/10.1073/pnas.1921223117
The paper
Sun, S., Luo, L., Liang, W., Yin, Q., Guo, J., Rush, A. M., Lv, Z., Liang, Q., Fischbach, M. A., Sonnenburg, J. L., Dodd, D., Davis, M. M., & Wang, F. (2020). Bifidobacterium alters the gut microbiota and modulates the functional metabolism of T regulatory cells in the context of immune checkpoint blockade. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1921223117

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.